Evidence map›Paper›PMID 30055352›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment.

Amy E DeZern, Richard J Jones, Robert A Brodsky

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Case 14: A 37-Year-Old Pregnant Woman With Thrombocytopenia.Journal of Korean medical science · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Amy E DeZernDepartment of Oncology, Sidney Kimmel Cancer Center, Baltimore Maryland; Department of Medicine, Division of Hematology, Johns Hopkins University, Baltimore, Maryland. Electronic address: adezern1@jhmi.edu.
Richard J JonesDepartment of Oncology, Sidney Kimmel Cancer Center, Baltimore Maryland; Department of Medicine, Division of Hematology, Johns Hopkins University, Baltimore, Maryland.
Robert A BrodskyDepartment of Oncology, Sidney Kimmel Cancer Center, Baltimore Maryland; Department of Medicine, Division of Hematology, Johns Hopkins University, Baltimore, Maryland.
Johns Hopkins University · USSidney Kimmel Cancer Center · US

Funding

Advancing Diagnostics and Therapeutics in Bone Marrow FailureK23HL123601 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DEZERN, AMY E · 2014 to 2017
$637k
NHLBI NIH HHS K23 HL123601
6 · The paper itself

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) often develops secondary to other bone marrow failure (BMF) disorders, especially aplastic anemia (AA). Patients with the AA/PNH syndrome may require treatment with both eculizumab to reduce intravascular hemolysis and the risk of thrombosis and allogeneic stem cell transplant for the severe BMF. There has been concern that eculizumab could adversely affect the outcomes for transplant in these patients. This is a retrospective, single-center study of severe AA (SAA)/PNH patients treated with eculizumab immediately before the start of conditioning for transplant. Metrics of engraftment and infectious outcomes are described. Eight patients with SAA/PNH and PNH-related symptoms were treated with eculizumab and then proceeded to transplant. All were successfully transplanted without adverse events related to C5 blockage before conditioning. All were also cured of their both PNH and SAA. Eculizumab is safe and efficacious in patients with PNH clones who require transplant. This is sometimes required to "bridge" patients before bone marrow transplantation and does not appear to adversely impact outcomes even when using HLA matched unrelated or haploidentical donors.

Indexed as

AdolescentAdultAntibodies, Monoclonal, HumanizedBone Marrow DiseasesBone Marrow TransplantationFemaleHemoglobinuria, ParoxysmalHumansMaleMiddle AgedRetrospective StudiesYoung AdultAntibodies, Monoclonal, HumanizedeculizumabAplastic anemiaEculizumabParoxysmal nocturnal hemoglobinuriaTransplant

Identifiers

PMID30055352
PMCPMC6286212
OpenAlexW2883392118

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.